Sensitive and specific detection of abnormal prion protein in blood could provide a diagnostic test or screening assay for animal and human prion diseases. Here, the application of an immunocapillary electrophoresis (ICE) method developed for sheep scrapie to brain, spleen and blood from patients with Creutzfeldt-Jakob disease (CJD) is described. The assay involves organic-solvent extraction, a competitive immunoassay using fluorescently labelled synthetic prion protein peptides and polyclonal antibodies specific for those sequences, and analysis by capillary electrophoresis using laser-induced fluorescence detection. The test was evaluated by using clinical blood specimens from patients with variant (n=5) or sporadic (n=4) CJD and patients initially suspected of having CJD who were given an alternative diagnosis (n=6). In this context, the ICE assay was specific, but incompletely sensitive (55 %). The method was unable to detect abnormal prion protein in variant CJD brain or spleen reference materials due to its loss during the extraction process.
Sensitive and specific detection of abnormal prion protein in blood could provide a diagnostic test or screening assay for animal and human prion diseases. Here, the application of an immunocapillary electrophoresis (ICE) method developed for sheep scrapie to brain, spleen and blood from patients with Creutzfeldt-Jakob disease (CJD) is described. The assay involves organic-solvent extraction, a competitive immunoassay using fluorescently labelled synthetic prion protein peptides and polyclonal antibodies specific for those sequences, and analysis by capillary electrophoresis using laser-induced fluorescence detection. The test was evaluated by using clinical blood specimens from patients with variant (n=5) or sporadic (n=4) CJD and patients initially suspected of having CJD who were given an alternative diagnosis (n=6). In this context, the ICE assay was specific, but incompletely sensitive (55 %). The method was unable to detect abnormal prion protein in variant CJD brain or spleen reference materials due to its loss during the extraction process.
In the absence of a foreign nucleic acid genome, diagnostic biochemical tests for the causative agents responsible for prion diseases rely on immunological methods to detect the abnormal, conformationally altered form of the hostencoded prion protein (PrP). The levels of this abnormal isoform, termed PrP Sc , that accumulate in the brain are sufficiently high to allow detection with conventional techniques such as immunohistochemistry and Western blotting, provided that pre-treatments are used that distinguish PrP Sc from the normal cellular form, termed PrP C . In particular, the partial protease resistance of PrP Sc and the protease sensitivity of PrP C have been exploited. Such methods have formed the basis of post-mortem diagnosis of the prion diseases scrapie in sheep, bovine spongiform encephalopathy (BSE) in cattle and Creutzfeldt-Jakob disease (CJD) in humans (reviewed by Soto, 2004) .
Since the first description of variant CJD (vCJD) (Will et al., 1996) , there have been 161 cases of vCJD in the UK (http:// www.cjd.ed.ac.uk/figures.htm) and an increasing number of other countries are now reporting cases. Among the human prion diseases, vCJD appears to have the broadest tissue distribution of PrP Sc at the post-mortem stage, including the lymphoreticular system (tonsil, spleen, appendix and lymph nodes), ganglia of the autonomic and peripheral nervous system (trigeminal, dorsal root, celiac and stellate ganglia), gastrointestinal tract, adrenal gland and thymus (Wadsworth et al., 2001; Haïk et al., 2003; Head et al., 2004a) . In vCJD, peripheral accumulation of PrP Sc appears to precede the onset of clinical symptoms (Hilton et al., 1998 (Hilton et al., , 2002 and this fact, coupled with the known infectivity of these tissues at the post-mortem stage (Bruce et al., 2001) , has prompted fears that individuals in a pre-or subclinical state might pose a risk of secondary infection to others by iatrogenic means (Hilton et al., 2004) .
The risk associated with blood was considered to be theoretical in nature until the demonstration that BSE and scrapie could be transmitted between sheep by blood transfusion, even when the donor sheep were in the preclinical phase of infection (Hunter et al., 2002) . Fears that similar events could occur in humans have been realized by the description of vCJD in two recipients of blood from donors who went on to develop vCJD (Llewelyn et al., 2004; HPA, 2006) . A case of transfusion-associated transmission has also been described in which the recipient died of another cause, but showed evidence of vCJD infection in the peripheral tissues (Peden et al., 2004) .
These events have added considerable urgency to the need for a blood test for CJD. Any tests capable of detecting PrP Sc in blood would require excellent biochemical sensitivity Minor, 2004) and any test with such biochemical sensitivity would also need to have an extremely high degree of test specificity in order to be implemented by the transfusion services (Johnson et al., 2001; Blajchman et al., 2004) .
Claims for a high degree of biochemical sensitivity have been made for a number of PrP assays, including conformationdependent immunoassay (Safar et al., 2002; Bellon et al., 2003) , immuno-PCR (Barletta et al., 2005) , immunocapillary electrophoresis (ICE) (Schmerr et al., 1999; Yang et al., 2005a, b; Jackman et al., 2006) and PrP Sc -selective ligandbased assays (Lane et al., 2004; Grosset et al., 2005) . We have evaluated one of these, ICE, by using clinical blood specimens from CJD patients [both sporadic CJD (sCJD) and vCJD] and diagnostically relevant neurological controls. We have also sought to determine whether post-mortem vCJD brain or spleen tissue might provide a source of positivecontrol material to validate and calibrate the ICE assay.
The ICE method has been described previously (Schmerr & Jenny, 1998; Schmerr et al., 1999; Yang et al., 2005a) . Buffycoat fractions of around 10 ml starting volume of whole blood are lysed by cycles of freezing and thawing and digested sequentially with DNase and proteinase K. Extraction is then performed by using a patented procedure and the material is purified by using hydrophilic-interaction chromatography as described previously (Schmerr & Alpert, 2000; Yang et al., 2005a) . The competitive immunoassay involves titration of a fluorescently labelled prion protein sequence synthetic peptide (FP) and a polyclonal antibody (Ab) raised to that sequence, such that free-zone capillary electrophoresis (CE) followed by laser-induced fluorescent (LIF) detection shows equivalent peak heights for the antibody-bound and free peptide. Test samples added to the developing immunocomplex are scored as positive if the bound/free peptide values are <70 % of the control values (Schmerr & Jenny, 1998; Schmerr et al., 1999) .
In this study, the ICE method was applied to archival buffycoat fractions of clinical blood specimens taken with consent for research from 15 patients suspected of having CJD. Of these 15 patients, five were cases of definite or probable vCJD, four were definite cases of sCJD and the remaining six (in whom a diagnosis of sCJD or vCJD was initially considered) were given an alternative final diagnosis. Buffycoat fraction had been prepared previously from EDTAtreated whole blood by using Histopaque-1077 (Sigma) and stored at 270 u C. DNase and proteinase K were used at 50 and 100 mg ml
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, respectively, and the assay employed the ovine FP 223 RESQAYYQRGASVIL 237 . Immunocomplex formation and CE-LIF analysis conditions were as described previously (Schmerr et al., 1999) . The peak height bound /peak height free for each sample was calculated and expressed as a percentage of the peak height bound /peak height free values obtained in the absence of extracted blood samples. The results are shown graphically (Fig. 1) . By using the predetermined 70 % value to define a positive result (Schmerr et al., 1999) , none of the samples from the neurologicalcontrol group tested positive, although one was borderline positive. By using the same criteria, two of the sCJD samples were positive and a third was borderline positive. Lastly, three out of the five vCJD samples were strongly positive. The assay therefore appears to detect the presence of protease-resistant PrP in the blood of a proportion of the patients with CJD, which is absent from blood samples from patients with other neurological conditions. However, the assay uses relatively large volumes (~10 ml) of an extremely limited resource (CJD patient blood specimens) and there is, as yet, no confirmatory assay for the presence of abnormal prion protein in CJD patient blood. Hence, we sought to investigate further the potential of ICE by employing FP sequences from different regions of the human prion protein and attempted to calibrate the assay by using autopsy vCJD brain and spleen reference materials that have been prepared by the National Institute of Biological Standards and Control (NIBSC) expressly for such purposes ) with the appropriate dilution of Ab for 16 h at 7 u C. The CE injection volume was 3?6 nl, corresponding to <4 amol FP analysed. The competition of relevant unlabelled peptide (UP) for the binding of antibody in all assays was found to be concentration-dependent (Fig. 2a) . Complete competition was obtained with the addition of the relevant UP at a concentration of <20 nM in each case and the 70 % cut-off was obtained at 0?41 nM for FP1, 0?25 nM for FP2 and 0?27 nM for FP5. As expected, the Ab/FP reactions were specific. Competition with irrelevant UP did not exceed 20 %, even when added to a concentration of up to 1 mM (Fig. 2b) . Surprisingly, when recombinant human PrP (rHuPrP) was added in the 11-546 nM range, no competition was observed in the FP1 and FP5 assays. There was concentration-dependent competition when rHuPrP was added to the FP2 assay and, although complete competition was not observed in the 11-546 nM range, the 70 % cut-off was reached at 109 nM rHuPrP. A typical example of such an assay is shown in Fig. 2(c) .
We then investigated whether the vCJD and Alzheimer's disease (AD) brain and spleen reference standards developed by NIBSC could serve as positive and negative controls in the ICE assay. These uncleared 10 % (w/v) tissue homogenates had been prepared in 10 % sucrose and were now centrifuged (420 g) to obtain separate sucrose supernatant (SS) and non-ionic detergent-solubilized sucroseinsoluble pellet (DS) fractions, both of which were tested by ICE. Western blotting demonstrated that nearly all of the protease-resistant PrP Sc was in the DS fraction of vCJD brain and that no protease-resistant PrP was detectable in either fraction of the AD brain (data not shown). Serial dilutions (10
- 10 28 ) were prepared from the 10 % homogenates in distilled water and 20 ml of each was used to spike 1 ml buffy-coat preparation made from platelet-depleted buffycoat residue packs (a discard product of platelet processing obtained from the Scottish National Blood Transfusion Service). The buffy coats were processed for ICE as described previously except that the levels of DNase and proteinase K were 100 and 70 mg ml 21 , respectively. Extracted samples were analysed by using the FP1, 2 and 5 assays and a prolonged separation that was found to be necessary to visualize the peaks in spiked buffy-coat samples. The peak-height ratios from the vCJD samples (brain and spleen) were expressed as a percentage of the result obtained with the negative-control AD samples (brain and spleen) and all samples were prepared and analysed in duplicate or triplicate. Methodological variations included sonication of the spike or spiked buffy coat prior to extraction and the addition or omission of formic acid in the extraction protocol. However, none of the samples fell below the 70 % level, nor was any trend apparent, either upward or downward, when a dilution series was analysed (data not shown). The processed samples were analysed for PrP Sc by Western blotting using the antibody 3F4. Although PrP Sc was readily detectable in the vCJD brain spike itself, it was undetectable in any extracted sample, including the vCJD brain, even when 20 ml 10 % brain extract had been used as a spike.
PrP
Sc was prepared from vCJD, sCJD and neurological control (Lewy body dementia; LBD) brain homogenates by repeated rounds of proteinase K digestion and centrifugal concentration (Head et al., 2004b) . Western blotting with 3F4 and 6H4 showed a tenfold enrichment for PrP Sc . The PrP Sc was also detectable on Western blots by the FP5 Ab. SDS-PAGE and Coomassie blue staining showed that the protein had been partially purified. These preparations were diluted (4610
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-4610 28 in 0?5 ml PBS) and the extraction and ICE analysis were performed. Neither the standard assay nor any methodological variation attempted produced evidence for PrP Sc detection in these samples by ICE. Finally, direct extraction and analysis were undertaken of the NIBSC vCJD and AD spleen samples (100 ml 10 % extract). This attempt was confounded by the apparent presence in vCJD and AD spleen of proteins or other moieties that interacted with the FP, producing artefactual distortion of the fluorescent peaks.
In an effort to determine at what point during the extraction procedure the PrP Sc was lost, samples were taken from key steps (Fig. 3) in the extraction process of the semi-purified vCJD and LBD brain homogenates and analysed by Western blotting (with 3F4, 6H4 and FP5 Ab) and dissociationenhanced lanthanide fluoroimmunoassay (DELFIA; 6H4 and 3F4 combination). These experiments indicated consistently that detectable PrP Sc failed to reach the hydrophilic interaction-chromatography step, but were rendered insoluble during the prior organic solvent-extraction steps.
These studies highlight some of the difficulties associated with the development of blood tests for prion diseases in general and the ICE assay in particular. The presence of PrP Sc in blood may be inferred from sheep-to-sheep and person-to-person transmission of infectivity by blood transfusion (Hunter et al., 2002; Llewelyn et al., 2004) . However, this proposition is only necessarily true if PrP Sc itself is indeed the infectious agent. Moreover, the physical forms of PrP Sc in blood and brain need not be identical. The finding that the rodent scrapie brain and murine vCJD plasma contain a fraction of protease-sensitive PrP Sc or proteasesensitive infectivity complicates matters further (Safar et al., 2002; Yakovleva et al., 2004 cases and a negative-control group to establish the sensitivity and specificity of the test in as close to the desired setting as possible. This may be done in sheep flocks 'at risk' of developing scrapie or animals infected experimentally with the agent of interest (Jackman et al., 2006) . Such studies are not possible when considering human prion diseases and the alternatives are to use blood specimens from vCJD patients or to spike normal blood specimens with infectious material from other sources.
We have performed both types of experiment. None of the experimental protocols that we tried were able to detect vCJD brain-or spleen-derived PrP Sc in the ICE assay; however, this appears to be a problem associated with sample processing rather than the competitive immunoassay or the analytical CE-LIF component. This is unfortunate, as the NIBSC reference materials are designed specifically to establish the analytical sensitivity of assays under development. In addition, matrix-associated problems were observed consistently with the spleen, involving interference with the competitive immunoassay, a problem that remains unresolved. The tests performed on clinical CJD blood specimens and relevant controls show some promise. By using the predetermined criteria for positivity, over half of the CJD blood specimens tested positive and none of the neurological controls were positive. It should, however, be noted that, when taken as a group, the results from the sCJD (mean, 77±23) and vCJD (mean, 76±49) patients differ little from the control group (mean, 78±5?7), a result similar to that found in the only other published study of ICE applied to CJD blood specimens (Cervenakova et al., 2003) .
Given the relatively large volume (~10 ml) of blood required for this assay, the extremely limited archives of blood available from patients with vCJD and the increasing demands on these resources from other assays under development, it seems unlikely that a larger ICE study on vCJD blood specimens will be performed in the near future. Since this work on vCJD blood was performed in 1999, there have been improvements made to both the ICE sample preparation and the analytical assay (Jackman & Schmerr, 2003; Yang et al., 2005a, b) . For these reasons, the validation of ICE technology may prove more readily achievable in the veterinary rather than the medical context.
